Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Medicaid

  • Home
  •  
  • Medicaid



  • Most Read
  • Latest Comments
  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

  • TGA approves Control Bionic’s autonomous wheelchair for commercial sales after NDIS delays
    TGA approves Control Bionic’s autonomous wheelchair for commercial sales after NDIS delays
    • News

  • They see me rollin, they lovin: Control Bionics receives $577k grant from the ALS association to develop self-driving wheelchairs
    They see me rollin, they lovin: Control Bionics receives $577k grant from the ALS association to develop self-driving wheelchairs
    • News

  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

  • Control Bionics and Deakin Uni collab will soon launch the world’s first mind-controlled wheelchair
    Control Bionics and Deakin Uni collab will soon launch the world’s first mind-controlled wheelchair
    • News

  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

    Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode

    The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code for the NeuroNode, patent technology by Control Bionics (ASX: CBL).  This approval, effective from 1 October 2024, introduces a reimbursement rate of US$4,300 for the NeuroNode, a significant enhancement from the previous reimbursement conditions. Control Bionics is a

    Read More
    Public
  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

    Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product

    The US Food and Drug Administration (FDA) has given the green light to respiratory imaging technology company 4DMedical (ASX: 4DX) for its CT-based lung ventilation analysis product (CT LVAS™). This FDA clearance will allow 4DMedical to leverage the US’s available CT hardware and boost its presence in the region. The FDA clearance follows the rollout

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.